Skip to main content
SpringerLink
Log in

Donepezil for the management of patients with Alzheimer’s disease: a good choice from among the cholinesterase inhibitors

  • New drugs and disease management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Dooley M, Lamb HM. Donepezil: a review of its use in Alzheimer’s disease. Drugs Aging 2000 Mar; 16(3): 199–226

    Article  PubMed  CAS  Google Scholar 

  2. Shintani EY, Uchida KM. Donepezil: an anticholinesterase inhibitor for Alzheimer’s disease. Am J Health System Pharm 1997 Dec 15; 54: 2805–10

    CAS  Google Scholar 

  3. Foster RH, Plosker GL. Donepezil: pharmacoeconomic implications of therapy. Pharmacoeconomics 1999 Jul; 16(1): 99–114

    Article  PubMed  CAS  Google Scholar 

  4. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial: the Donepezil Study Group. Dementia 1996 Nov–Dec; 7: 293–303

    PubMed  CAS  Google Scholar 

  5. Grutzendler J, Morris JC. Cholinesterase inhibitors for Alzheimer’s disease. Drugs 2001; 61(1): 41–52

    Article  PubMed  CAS  Google Scholar 

  6. Scott LJ, Goa KL. Galantamine: a review of its use in Alzheimer’s disease. Drugs 2000 Nov; 60(5): 1095–122

    Article  PubMed  CAS  Google Scholar 

  7. Drug Topics Red Book. Montvale (NJ): Medical Economics Company, 2000

  8. British National Formulary. No. 40. London: The Pharmaceutical Press, 2000 Sep

  9. Physician’s Desk Reference. 55th ed. Montvale (NJ): Medical Economics, 2001

  10. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer’s disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998 May 11; 158: 1021–31

    Article  PubMed  CAS  Google Scholar 

  11. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998 Jan; 50: 136–45

    Article  PubMed  CAS  Google Scholar 

  12. Burns A, Rosser M, Hecker J, et al. The effects of donepezil in Alzheimer’s disease — results from a multinational trial. Dementia Geriatr Cogn Disord 1999 May–Jun; 10: 237–44

    Article  CAS  Google Scholar 

  13. Giacobini E. Do cholinesterase inhibitors have disease-modifying effects in Alzheimer’s disease. CNS Drugs 2001; 15(2): 85–91

    Article  PubMed  CAS  Google Scholar 

  14. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society. JAMA 1997 Oct 22–29; 278: 1363–71

    Article  PubMed  CAS  Google Scholar 

  15. Friedhoff LT, Rogers SL. Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer’s disease — results of a preliminary evaluation [abstract]. Neurology 1997; 48(3) Suppl.: A100

    Google Scholar 

  16. Aricept prescribing information. Eisai/Pfizer. USA. 1996

  17. Aricept prescribing information. Eisai/Pfizer. UK. 1997

  18. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: an interim analysis of the results of US multicentre open label extension study. Eur Neuropsychopharmacol 1998 Feb; 8: 67–75

    Article  PubMed  CAS  Google Scholar 

  19. Pratt RD, Geldmacher D, Perdomo CA. An Evaluation of the long-term efficacy of donepezil in patients from a phase III clinical extension trial [abstract]. Neurology 1999 Apr; 52 Suppl. 2: 481–2

    Google Scholar 

  20. Lovestone S, Graham N, Howard R. Guidelines on drug treatments for Alzheimer’s disease. Lancet 1997 Jul 26; 350: 232–3

    Article  PubMed  CAS  Google Scholar 

  21. Barner EL, Gray SL. Donepezil use in Alzheimer disease. Ann Pharmacother 1998 Jan; 32: 70–7

    Article  PubMed  CAS  Google Scholar 

  22. Bryne GJA. Treatment of cognitive impairment in Alzheimer’s disease. Aust J Hosp Pharm 1998 Aug; 28: 261–6

    Google Scholar 

  23. Ernst RL, Hay JW, Fenn C, et al. Cognitive function and the costs of Alzheimer disease. Arch Neurol 1997 Jun; 54: 687–93

    Article  PubMed  CAS  Google Scholar 

  24. Leon J, Cheng C-K, Neumann PJ. Alzheimer’s disease care: costs and potential savings. Health Aff 1998 Nov–Dec; 17: 206–16

    Article  CAS  Google Scholar 

  25. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias of late life. Am J Psychiatry 1997 May; 154 Suppl.: 1–39

    Google Scholar 

  26. Homma A, Imai Y, Hariguchi S, et al. Late phase II clinical study of acetylcholinesterase inhibitor E 2020 in patients with Alzheimer-type dementia: 8-weeks double-blind parallel study in two groups, 2 mg/day, 0.1 mg/day [in Japanese]. Rinsho Hyoka 1998; 26(2): 185–207

    Google Scholar 

  27. Homma A, Imai Y, Hariguchi S, et al. Late phase II clinical study of acetylcholinesterase inhibitor E 2020 in patients with Alzheimer-type dementia: 24–48 weeks double-blind, placebo-controlled study [in Japanese]. Rinsho Hyoka 1998; 26(2): 209–31

    Google Scholar 

  28. Homma A, Imai Y, Hariguchi S, et al. Late phase II clinical study of acetylcholinesterase inhibitor E 2020 in patients with Alzheimer-type dementia: 12-weeks double-blind, placebo-controlled study, 3 mg/day, 5 mg/day [in Japanese]. Rinsho Hyoka 1998; 26(2): 251–84

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Donepezil for the management of patients with Alzheimer’s disease: a good choice from among the cholinesterase inhibitors. Drugs Ther. Perspect 17, 1–6 (2001). https://doi.org/10.2165/00042310-200117110-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200117110-00001

Keywords

Search

Navigation